-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Renowned Medical Oncologist, Investigator to Take Reins at IASLC in March
Longtime member Karen Kelly, MD, is set to become the new chief executive officer of the International Association for the Study of Lung Cancer. This March, Dr. Kelly, an internationally renowned lung cancer researcher, will begin collaborating closely with the IASLC Board of Directors and staff to achieve the goals and fulfill the mission established…
-
LungMATCH Program Models Best Practices for Empowering Patients
For people diagnosed with lung cancer and their families, understanding the illness and its treatments enough to participate in healthcare decisions can be challenging. Patients may not understand the benefits of personalized treatment or how to obtain it, whether that involves ensuring that tumor tissue undergoes biomarker testing, choosing among standard treatments, or seeking novel…
-
The Art and Science of Patient–Doctor Communication
When facing a grave illness, especially for the first time, many people are worried, frightened, and overwhelmed. They may have difficulty focusing their attention on daily tasks and experience skewed perceptions and memories based on intense emotions. This distress can also adversely affect the course and severity of disease and the success of its treatment.…
-
Keynote Addresses Lessons from SCLC Mouse Models
Experimental model systems are an indispensable part of research into SCLC. At the International Association for the Study of Lung Cancer’s 2021 Hot Topic Meeting: Small Cell Lung Cancer, keynote speaker Julien Sage, PhD, discussed the importance of these experimental models, specifically mouse models, in moving the field forward. Dr. Sage, who is the Elaine…
-
CDX Models Help Bring Personalized Treatment for SCLC a Step Closer
A growing body of research in SCLC has revealed greater phenotypic heterogeneity within this disease than previously realized. Circulating-tumor-cell-derived explant models (CDX) are providing researchers with a resource to facilitate personalization of SCLC treatment. At the International Association for the Study of Lung Cancer’s 2021 Hot Topic Meeting: Small Cell Lung Cancer, the opening keynote…
-
Preconditioning Program Shortens Postsurgical Hospital Stay for People with Lung Cancer
Reducing complications after lung cancer surgery could generate positive changes across healthcare, from better outcomes and quality of life to cost savings. Even a small decrease in incidence of postoperative complications could have meaningful results as they affect approximately 10% to 30% of those who undergo pulmonary resection and up to 50% of those treated…
-
Enhancing Understanding of Testing Applications, Best Practices: A Q&A with Dr. Lynette M. Sholl
Lynette M. Sholl, MD, Chief of Thoracic Pathology and Associate Director of the Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School, discusses her thoughts on the “new gold standard” of a combination approach—tissue and blood-based—to testing in lung cancer. Dr. Sholl answers several questions regarding the…